Literature DB >> 36127597

Plasma Lysosphingolipid Biomarker Measurement by Liquid Chromatography Tandem Mass Spectrometry.

Brandon B Stauffer1, Chunli Yu2,3.   

Abstract

Plasma lysosphingolipids are highly elevated in patients with Gaucher, Krabbe, Fabry, and Niemann-Pick diseases and tend to accumulate to a greater extent than their respective primary sphingolipids in the plasma of affected patients. In this chapter, we describe two liquid chromatography tandem mass spectrometry (LC-MS/MS) methods to measure plasma concentrations of four lysosphingolipids species. The first method described measures glucosylsphingosine (lyso-GL1) and galactosylsphingosine (psychosine), biomarkers that accumulate in Gaucher and Krabbe diseases, respectively. The second method measures globotriaosylsphingosine (lyso-Gb3) and sphingosylphosphorylcholine (lyso-SPM), biomarkers for Fabry and Niemann-Pick diseases, respectively. Each method utilizes isotope-labeled internal standards and multipoint calibration curves to quantify the analytes of interest. Briefly, plasma samples are mixed with five volumes of LC-MS grade methanol containing internal standard, and protein is removed via centrifugation. Supernatant is dried and resuspended in initial mobile phase. Samples are separated by liquid chromatography using either a BEH amide column (lyso-GL1 + psychosine) or a C18 column (lyso-Gb3 + lyso-SPM). Protonated analytes are measured by selected reaction monitoring (SRM) in positive electrospray ionization mode. Using these methods, we have observed elevations of these lyso- species in Gaucher, Fabry, and Niemann-Pick and successfully distinguished different subtypes reflecting the disease severity.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Fabry disease; Galactosylsphingosine (psychosine); Gaucher disease; Globotriaosylsphingosine (lyso-Gb3); Glucosylsphingosine (lyso-GL1); Krabbe disease; Liquid chromatography; Mass spectrometry; Niemann–Pick disease; Sphingosylphosphorylcholine (lyso-SPM)

Mesh:

Substances:

Year:  2022        PMID: 36127597     DOI: 10.1007/978-1-0716-2565-1_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

Review 1.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

2.  Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.

Authors:  Nick Dekker; Laura van Dussen; Carla E M Hollak; Herman Overkleeft; Saskia Scheij; Karen Ghauharali; Mariëlle J van Breemen; Maria J Ferraz; Johanna E M Groener; Mario Maas; Frits A Wijburg; Dave Speijer; Anna Tylki-Szymanska; Pramod K Mistry; Rolf G Boot; Johannes M Aerts
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

3.  Psychosine, a marker of Krabbe phenotype and treatment effect.

Authors:  M L Escolar; B T Kiely; E Shawgo; X Hong; M H Gelb; J J Orsini; D Matern; M D Poe
Journal:  Mol Genet Metab       Date:  2017-05-22       Impact factor: 4.797

4.  Measurement of psychosine in dried blood spots--a possible improvement to newborn screening programs for Krabbe disease.

Authors:  Coleman T Turgeon; Joseph J Orsini; Karen A Sanders; Mark J Magera; Thomas J Langan; Maria L Escolar; Patricia Duffner; Devin Oglesbee; Dimitar Gavrilov; Silvia Tortorelli; Piero Rinaldo; Kimiyo Raymond; Dietrich Matern
Journal:  J Inherit Metab Dis       Date:  2015-03-12       Impact factor: 4.982

5.  Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.

Authors:  Eduard Orvisky; Joseph K Park; Mary E LaMarca; Edward I Ginns; Brian M Martin; Nahid Tayebi; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2002-08       Impact factor: 4.797

6.  Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.

Authors:  Deborah Elstein; Björn Mellgard; Quinn Dinh; Lan Lan; Yongchang Qiu; Claudia Cozma; Sabrina Eichler; Tobias Böttcher; Ari Zimran
Journal:  Mol Genet Metab       Date:  2017-08-24       Impact factor: 4.797

7.  Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease.

Authors:  O Nilsson; L Svennerholm
Journal:  J Neurochem       Date:  1982-09       Impact factor: 5.372

8.  Krabbe disease: a galactosylsphingosine (psychosine) lipidosis.

Authors:  L Svennerholm; M T Vanier; J E Månsson
Journal:  J Lipid Res       Date:  1980-01       Impact factor: 5.922

9.  Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.

Authors:  Pramod K Mistry; Elena Lukina; Hadhami Ben Turkia; Suma P Shankar; Hagit Baris; Marwan Ghosn; Atul Mehta; Seymour Packman; Gregory Pastores; Milan Petakov; Sarit Assouline; Manisha Balwani; Sumita Danda; Evgueniy Hadjiev; Andres Ortega; Sebastiaan J M Gaemers; Regina Tayag; M Judith Peterschmitt
Journal:  Am J Hematol       Date:  2017-10-03       Impact factor: 10.047

10.  The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease.

Authors:  Adam J Guenzel; Coleman T Turgeon; Kim K Nickander; Amy L White; Dawn S Peck; Gisele B Pino; April L Studinski; Vinod K Prasad; Joanne Kurtzberg; Maria L Escolar; Maria Laura Duque Lasio; Joan E Pellegrino; Ai Sakonju; Rachel E Hickey; Natalie M Shallow; Margie A Ream; Joseph J Orsini; Michael H Gelb; Kimiyo Raymond; Dimitar K Gavrilov; Devin Oglesbee; Piero Rinaldo; Silvia Tortorelli; Dietrich Matern
Journal:  Genet Med       Date:  2020-02-24       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.